Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteglycovaxyn.com
CategoryBioTech
Phone+41 44 733 85 85
Employees
Descriptionbioconjugate vaccines

Offices

GlycoVaxyn AG
Grabenstrasse 3
Schlieren, 8952, CHE

Funding

TOTAL $22.1M
FUNDING TOTAL $22.1M
Venture Round, 7/2006
Index Ventures
Sofinnova Partners
$817k
Series B, 3/2009
Edmond de Rothschild Venture Capital
Index Ventures
Sofinnova Partners
$21.3M

Tags

GlycoVaxyn

GlycoVaxyn has built a broad portfolio of conjugate vaccines against common severe bacterial infections based on its unique, proprietary invivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spinout of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland.

Recent Milestones

  • Dollar
    GlycoVaxyn received $21.3M in Series B funding. (3/5/09)
    Posted 6/19/09 at 6:12am via bio-medicine.org
  • Dollar
    GlycoVaxyn received $817k in Venture Round funding. (7/1/06)
    Posted 4/30/10 at 11:42pm

Videos

Screenshots

Sources

  1. EDGAR [edit]
  2. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners (bio-medicine.org) [edit]
Edit This Page
Last Edited 4/2/12

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy